CalciMedica Inc
CALC0.600USD
-0.011-1.77%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
8.56MMarket Cap
LossP/E TTM
More Details of CalciMedica Inc Company
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
CalciMedica Inc Info
Ticker SymbolCALC
Company nameCalciMedica Inc
IPO dateSep 25, 2020
CEOLeheny (A. Rachel)
Number of employees14
Security typeOrdinary Share
Fiscal year-endSep 25
Address505 Coast Boulevard South
CityLA JOLLA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92037
Phone18589525500
Websitehttps://calcimedica.com/
Ticker SymbolCALC
IPO dateSep 25, 2020
CEOLeheny (A. Rachel)
Company Executives of CalciMedica Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert N. Wilson
Mr. Robert N. Wilson
Independent Chairman of the Board
Independent Chairman of the Board
422.03K
+4500.00%
Mr. Eric W. Roberts
Mr. Eric W. Roberts
Chief Business Officer, Director
Chief Business Officer, Director
253.48K
+15000.00%
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Director
Director
90.73K
--
Dr. Sudarshan Hebbar, M.D.
Dr. Sudarshan Hebbar, M.D.
Chief Medical Officer
Chief Medical Officer
61.54K
+15539.00%
Mr. Stephen Bardin
Mr. Stephen Bardin
Chief Financial Officer
Chief Financial Officer
41.00K
+1000.00%
Dr. A. Rachel Leheny, Ph.D.
Dr. A. Rachel Leheny, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Fred Middleton
Mr. Fred Middleton
Independent Director
Independent Director
--
--
Mr. Allan L. Shaw
Mr. Allan L. Shaw
Independent Director
Independent Director
--
--
Mr. Michael J. Dunn
Mr. Michael J. Dunn
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Kenneth A. Stauderman, Ph.D.
Dr. Kenneth A. Stauderman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert N. Wilson
Mr. Robert N. Wilson
Independent Chairman of the Board
Independent Chairman of the Board
422.03K
+4500.00%
Mr. Eric W. Roberts
Mr. Eric W. Roberts
Chief Business Officer, Director
Chief Business Officer, Director
253.48K
+15000.00%
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Director
Director
90.73K
--
Dr. Sudarshan Hebbar, M.D.
Dr. Sudarshan Hebbar, M.D.
Chief Medical Officer
Chief Medical Officer
61.54K
+15539.00%
Mr. Stephen Bardin
Mr. Stephen Bardin
Chief Financial Officer
Chief Financial Officer
41.00K
+1000.00%
Dr. A. Rachel Leheny, Ph.D.
Dr. A. Rachel Leheny, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 3
Updated: Wed, Dec 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sanderling Ventures
16.72%
Alafi Capital Company, LLC
10.99%
Deerfield Management Company, L.P.
9.03%
Chernett (Jorey)
7.88%
Valence Investments SPV IV LLC
5.13%
Other
50.24%
Shareholders
Shareholders
Proportion
Sanderling Ventures
16.72%
Alafi Capital Company, LLC
10.99%
Deerfield Management Company, L.P.
9.03%
Chernett (Jorey)
7.88%
Valence Investments SPV IV LLC
5.13%
Other
50.24%
Shareholder Types
Shareholders
Proportion
Venture Capital
27.82%
Individual Investor
18.57%
Hedge Fund
14.64%
Investment Advisor/Hedge Fund
7.42%
Investment Advisor
5.93%
Corporation
5.13%
Research Firm
0.10%
Other
20.39%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
58
8.01M
64.76%
--
2025Q3
59
8.01M
66.57%
+130.13K
2025Q2
55
7.88M
59.90%
-241.93K
2025Q1
51
8.12M
59.34%
-171.63K
2024Q4
60
7.12M
50.52%
+796.30K
2024Q3
56
5.92M
60.39%
+87.63K
2024Q2
54
5.84M
57.49%
-574.62K
2024Q1
54
6.41M
55.05%
+498.16K
2023Q4
50
2.70M
15.95%
-73.63K
2023Q3
56
2.78M
15.72%
-86.77K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sanderling Ventures
2.41M
16.72%
--
--
Mar 31, 2025
Alafi Capital Company, LLC
1.58M
10.99%
+287.48K
+22.19%
Jul 22, 2025
Deerfield Management Company, L.P.
1.30M
9.03%
--
--
Sep 30, 2025
Chernett (Jorey)
1.13M
7.88%
+1.13M
--
Nov 24, 2025
Valence Investments SPV IV LLC
739.33K
5.13%
--
--
Mar 31, 2025
Soleus Capital Management, L.P.
683.90K
4.75%
-100.00K
-12.76%
Sep 30, 2025
Aisling Capital Management LP
521.11K
3.62%
--
--
Sep 30, 2025
Lytton (Laurence W)
468.94K
3.26%
-25.93K
-5.24%
Sep 30, 2024
Pengana Capital Group Limited
449.00K
3.12%
--
--
May 31, 2025
Wilson (Robert N)
422.03K
2.93%
+4.50K
+1.08%
Jul 18, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
